

CITATION REPORT

List of articles citing

Risk factors in predicting a poor response to sildenafil citrate in elderly men with erectile dysfunction

DOI: 10.1111/j.1464-410x.2005.05301.x
BJU International, 2005, 95, 366-70.

Source: <https://exaly.com/paper-pdf/38175106/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
63	Current World Literature. <i>Current Opinion in Urology</i> , 2005 , 15, 410-415	2.8	
62	Development and evaluation of a prostate sexual rehabilitation clinic: a pilot project. <i>BJU International</i> , 2005 , 96, 1360-4	5.6	22
61	ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: scientific background and rationale. <i>Aging Male</i> , 2005 , 8, 59-74	2.1	85
60	PDE-5 inhibitors: current status and future trends. <i>Urologic Clinics of North America</i> , 2005 , 32, 511-25, viii	2.9	25
59	Does testosterone have a role in erectile function?. <i>American Journal of Medicine</i> , 2006 , 119, 373-82	2.4	74
58	The role of testosterone in erectile function and dysfunction. <i>The Journal of Men's Health & Gender: the Official Journal of the International Society for Men's Health & Gender</i> , 2006 , 3, 292-298		1
57	Erectile and sexual dysfunction in the aging diabetic male. <i>Aging Health</i> , 2006 , 2, 1025-1034		2
56	Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled study. <i>Andrologia</i> , 2006 , 38, 61-8	2.4	49
55	The evolving role of testosterone in the treatment of erectile dysfunction. <i>International Journal of Clinical Practice</i> , 2006 , 60, 1087-92	2.9	56
54	Recent insights into androgen action on the anatomical and physiological substrate of penile erection. <i>Asian Journal of Andrology</i> , 2006 , 8, 3-9	2.8	51
53	Male hypogonadism. Part I: Epidemiology of hypogonadism. <i>International Journal of Impotence Research</i> , 2006 , 18, 115-20	2.3	50
52	A meta-regression analysis of treatment effect modifiers in trials with flexible-dose oral sildenafil for erectile dysfunction in broad-spectrum populations. <i>International Journal of Impotence Research</i> , 2006 , 18, 559-65	2.3	11
51	Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido). <i>World Journal of Urology</i> , 2006 , 24, 639-44	4	38
50	Predictors of tadalafil efficacy in men with erectile dysfunction: the SURE study comparing two dosing regimens. <i>Journal of Sexual Medicine</i> , 2006 , 3, 1050-1058	1.1	8
49	Tobacco education: emphasizing impotence as a consequence of smoking. <i>American Journal of Health-System Pharmacy</i> , 2006 , 63, 2509-12	2.2	2
48	Testosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents. <i>International Journal of Impotence Research</i> , 2007 , 19, 2-24	2.3	57
47	Testosterone and Erection: Practical Management for the Patient with Erectile Dysfunction. <i>European Urology Supplements</i> , 2007 , 6, 868-873	0.9	8

46	Treatment options for erectile dysfunction. <i>Endocrinology and Metabolism Clinics of North America</i> , 2007 , 36, 465-79	5.5	32
45	Recent trends in the treatment of testosterone deficiency syndrome. <i>International Journal of Urology</i> , 2007 , 14, 981-5	2.3	14
44	Severity of ED: relationship to treatment-seeking and satisfaction with treatment using PDE5 inhibitors. <i>Journal of Sexual Medicine</i> , 2007 , 4, 145-151	1.1	24
43	Combination therapy with phosphodiesterase type V inhibitors and testosterone. <i>Current Sexual Health Reports</i> , 2008 , 5, 135-140	1.2	10
42	How to optimise treatment of erectile dysfunction above and beyond the beneficial effects of a phosphodiesterase type 5 inhibitor. <i>Journal of Men's Health</i> , 2008 , 5, 163-170	1.2	2
41	Testosterone and erectile dysfunction. <i>Journal of Andrology</i> , 2008 , 29, 593-604		48
40	The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. <i>Journal of Andrology</i> , 2009 , 30, 23-32		179
39	Basic consensus document on late-onset hypogonadism. <i>Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion</i> , 2008 , 55, 5-28		5
38	Erectile dysfunction and testosterone deficiency. <i>Frontiers of Hormone Research</i> , 2009 , 37, 108-122	3.5	44
37	Testosterone deficiency: a common, unrecognized syndrome. <i>Nature Reviews Urology</i> , 2008 , 5, 388-96		48
36	. 2008 ,		13
35	Non-invasive management of primary phosphodiesterase type 5 inhibitor failure in patients with erectile dysfunction. <i>Therapeutic Advances in Urology</i> , 2009 , 1, 235-42	3.2	7
34	The efficacy and safety of udenafil [Zydena] for the treatment of erectile dysfunction in hypertensive men taking concomitant antihypertensive agents. <i>Journal of Sexual Medicine</i> , 2009 , 6, 3166-76	1.1	19
33	Gender differences in tail-skin flushing induced by nitrates and phosphodiesterase type 5 inhibitors in a climacteric mouse model. <i>European Journal of Pharmacology</i> , 2009 , 624, 66-70	5.3	5
32	Toward a new EPOCH optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction. <i>International Journal of Clinical Practice</i> , 2009 , 63, 1214-30	2.9	17
31	Smoking and urological disease. <i>BJU International</i> , 2009 , 103, 1317-9	5.6	2
30	Endothelial antioxidant administration ameliorates the erectile response to PDE5 regardless of the extension of the atherosclerotic process. <i>Journal of Sexual Medicine</i> , 2010 , 7, 1247-53	1.1	23
29	Endocrine aspects of male sexual dysfunctions. <i>Journal of Sexual Medicine</i> , 2010 , 7, 1627-56	1.1	142

28	What should I do with a 60-year old man with a slightly low serum total testosterone concentration and normal levels of serum gonadotrophins? <i>Clinical Endocrinology</i> , 2010 , 72, 584-8	3.4	4
27	Hypogonadism, erectile dysfunction, and type 2 diabetes mellitus: what the clinician needs to know. <i>Postgraduate Medicine</i> , 2010 , 122, 165-75	3.7	50
26	Cardiovascular diseases and erectile dysfunction: the two faces of the coin of androgen deficiency. <i>Andrologia</i> , 2011 , 43, 1-8	2.4	19
25	Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). <i>Journal of Sexual Medicine</i> , 2011 , 8, 284-93	1.1	111
24	Combination of testosterone and vardenafil increases female sexual functioning in sub-primed rats. <i>Journal of Sexual Medicine</i> , 2011 , 8, 989-1001	1.1	8
23	Erectile dysfunction and hypertension: impact on cardiovascular risk and treatment. <i>International Journal of Hypertension</i> , 2012 , 2012, 627278	2.4	44
22	Response to on-demand vardenafil was improved by its daily usage in hypertensive men. <i>Urology</i> , 2012 , 80, 858-64	1.6	9
21	Sexual dysfunction in men with type 2 diabetes. <i>Postgraduate Medical Journal</i> , 2012 , 88, 152-9	2	58
20	Androgens and Endocrine Function in Aging Men: Effects on Sexual and General Health. 2012 , 122-153		
19	Impotence. 2013 , 379-388		
18	What next for phosphodiesterase inhibitor failures?. <i>BJU International</i> , 2014 , 113, 654-5	5.6	
17	Nonresponse to phosphodiesterase 5 inhibitors in erectile dysfunction. Part 1. <i>Human Andrology</i> , 2014 , 4, 23-29	1	0
16	Impact of low testosterone on response to treatment with tadalafil 5 mg once daily for erectile dysfunction. <i>Urology</i> , 2014 , 83, 1326-33	1.6	14
15	Hypogonadal symptoms in young men are associated with a serum total testosterone threshold of 400 ng/dL. <i>BJU International</i> , 2015 , 116, 142-6	5.6	19
14	Clinical predictive factors of sildenafil response: a penile hemodynamic study. <i>Andrology</i> , 2015 , 3, 241-6	4.2	5
13	Erectile Dysfunction in the Elderly. <i>Current Geriatrics Reports</i> , 2015 , 4, 33-43	1.3	3
12	Impact of Baseline Total Testosterone Level on Successful Treatment of Sexual Dysfunction in Men Taking Once-Daily Tadalafil 5 mg for Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: An Integrated Analysis of Three Randomized Controlled Trials. <i>Journal of Sexual Medicine</i> , 2016 , 13, 843-51	1.1	7
11	Effects of taking tadalafil 5 mg once daily on erectile function and total testosterone levels in patients with metabolic syndrome. <i>Andrologia</i> , 2017 , 49, e12751	2.4	9

10	Effect of testosterone replacement therapy on sexual function and glycemic control among hypogonadal men with type 2 diabetes mellitus. <i>International Journal of Impotence Research</i> , 2019 , 31, 25-30	2.3	9
9	Is There a Point to Performing a Penile Duplex Ultrasound?. <i>Journal of Sexual Medicine</i> , 2019 , 16, 1574-1580		2
8	Hypogonadism and metabolic syndrome in nigerian male patients with both type 2 diabetes and hypertension. <i>International Journal of Endocrinology and Metabolism</i> , 2014 , 12, e10749	1.8	8
7	Hypogonadism and Metabolic Syndrome in Nigerian Male Patients With Both Type 2 Diabetes and Hypertension. <i>International Journal of Endocrinology and Metabolism</i> , 2014 , 12,	1.8	2
6	Impotence. 2009 , 385-393		
5	Causes of primary refractoriness to the treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors and means to overcome it. <i>Problemy Endokrinologii</i> , 2011 , 57, 42-45	0	
4	Phosphodiesterase-5 Inhibitors in Cardioprotection. 2013 , 439-458		
3	Can we rely on total testosterone measurement to exclude hypogonadism in erectile dysfunction?. <i>International Journal of Impotence Research</i> , 2022 ,	2.3	
2	The Impact of Testosterone on Erectile Function. 2022 , 3, 113-124		0
1	Does Testosterone Salvage PDE5i Non-Responders? A Scoping Review. 2023 , 4, 117-127		0